Stocks · News reference

Lakewood-Amedex Biotherapeutics shares are trading higher after the company announced preclinical data in UTI and pulmonary infection indications in animal models treated with Bisphosphocin compounds.

Oct 7, 2026, 12:11 PMBenzinga Newsdesk

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Oct 7, 2026, 12:11 PM
Checked: Oct 7, 2026, 12:11 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaOct 7, 2026, 12:41 PMBenzinga Newsdesk
LABT stock has given up its prior gain. Lakewood-Amedex Biotherapeutics shares were trading higher after the company announced preclinical data in UTI and pulmonary infection indications in animal models treated with Bisphosphocin compounds.
LABT
BenzingaOct 7, 2026, 12:07 PMBenzinga Newsdesk
Lakewood-Amedex Says Nu-8 Shows Up To 97% Inhibition Of E. Coli Growth In Rodent Urinary Tract Infection Model
LABT
BenzingaSep 28, 2026, 12:54 PMBenzinga Newsdesk
Lakewood-Amedex Biotherapeutics shares are trading higher after the company announced Minimum Inhibitory Concentration data from recent clinical isolates for its lead clinical candidate, Nu-3.
LABT